Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Vanowel Efavirenz, Tenofovir & Emtricitabine Tablets
Vanowel is a combination antiretroviral medication designed to effectively manage HIV-1 infection. It contains Efavirenz, Tenofovir, and Emtricitabine, working together to suppress viral replication, improve immune response, and prevent disease progression.
Uses of Vanowel Efavirenz, Tenofovir & Emtricitabine Tablets
First-line treatment of HIV-1 infection
Reduction of viral load and improvement of CD4 cell count
Prevention of HIV transmission when used as part of a comprehensive treatment plan
Benefits of Vanowel Efavirenz, Tenofovir & Emtricitabine Tablets
Highly effective once-daily regimen for HIV treatment
Reduces the risk of HIV progression and opportunistic infections
Improves immune function by increasing CD4 cell levels
Well-tolerated with proven long-term efficacy
Mechanism of Action of Vanowel Efavirenz, Tenofovir & Emtricitabine Tablets
Vanowel inhibits key enzymes needed for HIV replication:
Efavirenz blocks reverse transcriptase, preventing viral RNA from converting into DNA.
Tenofovir and Emtricitabine act as nucleoside reverse transcriptase inhibitors (NRTIs), further preventing viral DNA synthesis.
Together, they reduce viral load and maintain immune system function.